Bastani Mohammad-Navid, Jalilian Shahram, Bahreiny Seyed Sobhan, Makvandi Manoochehr, Aghaei Mojtaba, Mansouri Zahra, Karamali Negin, Sakhavarz Tannaz, Amraei Mahdi, Harooni Elnaz
Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Biomark Med. 2024 Dec;18(24):1135-1148. doi: 10.1080/17520363.2024.2432325. Epub 2024 Dec 1.
Surfactant Protein D (SP-D), a key component of the innate immune system, has attracted significant interest for its potential role in the pathophysiology and prognosis of COVID-19. This systematic review and meta-analysis aim to clarify the prognostic importance of SP-D levels in COVID-19 patients.
A comprehensive literature search was conducted using PubMed, Web of Science, Cochrane Library, Scopus, EMBASE, and Google Scholar, covering studies published from January 2000 to January 2024. The inclusion criteria focused on studies measuring SP-D levels in the serum or plasma of COVID-19 patients, comparing severe and non-severe cases. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model to assess overall effect sizes. Meta-regressions and subgroup analyses were performed to identify potential sources of heterogeneity, including patient age, assay techniques, and gender ratio.
The meta-analysis incorporated data from nine studies involving 5,410 COVID-19 patients. Elevated SP-D levels were significantly correlated with increased disease severity, yielding an SMD of 0.642 (95% CI: 0.314 to 0.870; = 0.012).
This meta-analysis confirms the prognostic significance of SP-D in the context of COVID-19. Elevated SP-D levels are associated with severe disease outcomes, highlighting its potential as a prognostic biomarker.
表面活性蛋白D（SP-D）是先天性免疫系统的关键组成部分，因其在新冠病毒疾病（COVID-19）的病理生理学和预后中的潜在作用而备受关注。本系统评价和荟萃分析旨在阐明SP-D水平在COVID-19患者预后中的重要性。
使用PubMed、科学网、考克兰图书馆、Scopus、EMBASE和谷歌学术进行全面的文献检索，涵盖2000年1月至2024年1月发表的研究。纳入标准侧重于测量COVID-19患者血清或血浆中SP-D水平并比较重症和非重症病例的研究。使用随机效应模型计算标准化平均差（SMD）及其95%置信区间（CI），以评估总体效应大小。进行荟萃回归和亚组分析以确定潜在的异质性来源，包括患者年龄、检测技术和性别比例。
荟萃分析纳入了9项研究的数据，涉及5410名COVID-19患者。SP-D水平升高与疾病严重程度增加显著相关，标准化平均差为0.642（95%CI：0.314至0.870；P = 0.012）。
这项荟萃分析证实了SP-D在COVID-19背景下的预后意义。SP-D水平升高与严重疾病结局相关，突出了其作为预后生物标志物的潜力。
